Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Voriconazole 2Social Determinants of Health 2trastuzumab deruxtecan 1sacituzumab govitecan 1glucarpidase 1denileukin diftitox 1bismuth tripotassium dicitrate 1Ofloxacin 1Metronidazole 1Methotrexate 1Levofloxacin 1Immunotherapy, Adoptive 1Esomeprazole 1Dihydrouracil Dehydrogenase (NADP) 1Clarithromycin 1CTLA-4 Antigen 1Antineoplastic Agents 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Drug-Related Side Effects and Adverse Reactions × denileukin diftitox × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡